Abstract
Introduction
A drug is a compound that exhibits action for the treatment of different diseases or to cure or diagnose the diseases. Different companies are in the progress for the production different APIs or the drugs. Analytical chemistry is divided into two types 1. Quantitative analysis: It is concerned with the exact amount present in the sample, 2. Qualitative analysis: It is concerned with the sample representation in the form of numbers. The study of analytical chemistry provides ideal training for nearly all scientists course in quantitative analysis. In all the instrumental techniques available UV spectrophotometric technique is more simple, sensitive and precise. Different techniques are available for the
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Chromatography
The mixture of compounds is separated by chromatographic technique. Most commonly used chromatographic techniques are 1. Gas chromatography 2. Paper chromatography 3. High performance thin layer chromatography
Plan of Work
Step-1 Solubility studies.
Step-2 Determination of wavelength of Ambroxol, Montelukast and Levocetrizine.
Step-3 Method development and to optimize the mobile phase and flow rates for proper resolution and Retention time.
Step-4 Validation was developed as per the ICH (International Conference on Harmonisation).
Need For The Study

Analytical method development for pharmaceutical formulations
Quality investigation plays a very important role in quality specification establishment of chemical drugs. The number of drugs introduced into the market every year. Very often there is a time lag from the date of introduction of a drug into the market to the date of its inclusion in pharmacopoeias. Hence, standards and analytical procedures for these drugs may not be available in the pharmacopoeias. It becomes necessary, therefore to develop newer analytical methods for such drugs. Basic criteria for new method development of drug analysis:
• The drug or drug combination may not be official in any pharmacopoeias.
• A proper analytical procedure for the drug may not be available in the literature due to patent regulations.
• Analytical methods may not be available for the drug in the form of a formulation due to the interference caused by the formulation excipients.
• Analytical methods for a drug in combination with other drugs may not be available.
• The existing analytical procedures may require expensive reagents and solvents. It may also involve cumbersome extraction and separation procedures, and these may not be reliable.
• Analytical method development provides the support to track the quality of the product from batch to batch. 
Half-life: 7-12 h
Indication
Ambroxol is indicated as "secretolytic therapy in bronchopulmonary diseases associated with abnormal mucus secretion and impaired mucus transport. It promotes mucus clearance, facilitates expectoration and eases productive cough, allowing patients to breathe freely and deeply. Ambroxol also provides pain relief in acute sore throat. Pain in sore throat is the hallmark of acute pharyngitis.
Side effects
Field tests to date have not uncovered specific contraindications of Ambroxol. However, caution is suggested for patients with gastric ulceration, and usage during the first trimester of pregnancy is not recommended.
Montelukast
Montelukast is a leukotriene receptor antagonist (LTRA) used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies. It is usually administered orally. Montelukast blocks the action of leukotriene D4 on the cysteinyl leukotriene receptor CysLT1 in the lungs and bronchial tubes by binding to it. This reduces the bronchoconstriction otherwise caused by the leukotriene, and results in less inflammation. Because of its method of operation, it is not useful for the treatment of acute asthma attacks. Again because of its very specific locus of operation, it does not interact with other allergy medications such as theophylline. Montelukast is marketed in United States and many other countries by Merck & Co. with the brand name Singulair®. It is available as oral tablets, chewable tablets, and oral granules. In India and other countries, it is also marketed under the brand name Montair®, produced by Indian company Cipla.
Structure
IUPAC name
Molecular weight: 586.183
Chemical formula: C35H36ClNO3S
Mechanism of action
Montelukast selectively antagonizes leukotriene D4 (LTD4) at the cysteinyl leukotriene receptor, CysLT1, in the human airway. Montelukast inhibits the actions of LTD4 at the CysLT1receptor, preventing airway edema, smooth muscle contraction, and enhanced secretion of thick, viscous mucus.
Indication
For the treatment of asthma. Montelukast is used for several conditions including asthma, exercise induced bronchospasm, allergic rhinitis, primary dysmenorrhoea (i.e. dysmenorrhoea not associated with known causes; see dysmenorrhea causes), and urticaria.
Adverse effects
The side effects include severe behavioural changes (including suicidal thoughts), angioedema, erythema multiforme, and liver problems. 
Levocetrizine
Levocetirizine is an inverse agonist that decreases activity at histamine H1 receptors. This in turn prevents the release of other allergy chemicals and increased blood supply to the area and provides relief from the typical symptoms of hay fever. It does not prevent the actual release of histamine from mast cells.
Structure
IUPAC name
2-(2-{4-[(R)-(4-chlorophenyl)(phenyl)methyl] piperazin-1-yl}ethoxy)acetic acid.
Chemical formula: C21H25ClN2O3
Molecular weight: 388.89
Mechanism of action
Levocetirizine, the active enantiomer of cetirizine, is an anti-histamine; its principal effects are mediated via selective inhibition of H1 receptors. The antihistaminic activity of levocetirizine has been documented in a variety of animal and human models. In vitro binding studies revealed that levocetirizine has an affinity for the human H1-receptor 2-fold higher than that of cetirizine (Ki=3 nmol/L vs. 6 nmol/L, respectively). This increased affinity has unknown clinical relevance. In Nepal levocetirizine is available in tablet with brand name Curin manufactured by Beximco Pharma.
Indication
Levocetirizine is indicated for the relief of symptoms associated with allergic rhinitis (seasonal and perennial) in adults and children 6 years of age and older.
Availability
On 31 January 2017, the Food and Drug Administration approved Xyzal as an over-the-counter drug.
Method Development
Method development of ambroxol, montelukast and levocetrizine
Preparation of standard solution for all trails
Weigh 15 mg of Ambroxol and 10 mg of Montelukast and 2.5 mg of Levocetrizine in 100 ml of volumetric flask and make up the volume with mobile phase or Diluent upto the mark. From the above solution pipette out 1.5 ml from ambroxol and 1 ml from montelukast and 0.25 ml from Levocetrizine (2.75 ml) and transfer it to 10 ml volumetric flask make up the volume up to the diluent (27.5 µg/ml) ( Table 1) . 
Trial 4 observation
➢ Peak response of Lecocetrizine was very less. ➢ Efficiency was not good for Ambroxol. ➢ Hence it is not optimized.
Trial 5 observation (optimized)
➢ Efficiency was good for all the drugs . ➢ Assymetric factor was good for all the drugs. ➢ All suitable parameters are satisfactory. ➢ Hence we considered trail-5 as optimized trail (Table  2) .
Validation
Validation is a documented evidence that the method which does what it is intended to it. There are 9 parameters [4] [5] [6] [7] . ➢ Assay ➢ Apecificity ➢ Linearity ➢ Accuracy ➢ Precision ➢ LOD (limit of detection) ➢ LOQ (limit of quantification) ➢ Robustness ➢ Ruggedness 
Assay
To determine the percentage of purity we will perform the Assay. We will inject 6 injections of standard and 6 injections of sample.
Preparation of standard
Weigh 15 mg of Ambroxol and 10mg of Montelukast and 2.5 mg of Levocetrizine in 100ml of volumetric flask and make up the volume with mobile phase or dupto the mark. From the above solution pipette out 1.5 ml from ambroxol and 1 ml from Montelukast and 0.25 ml from Levocetrizine (2.75 ml) and transfer it to 10 ml volumetric flask make up the volume up to the diluent (27.5 µg/ml). 6 ml volumetric flask from the above stock solution pipette out 2.75 ml and transfer intp 10 ml volumetric flask and make up the volume with mobile phase.
Sample preparation
Acceptance criteria: 90-110%
Observation
The amount of Ambroxol, Montelukast and Levocetrizine present in the taken dosage form was found to be 98.81%, 102.56% and 98.62% respectively (Table 3) . 
Linearity
Linearity is an analytical method it will determine its ability to obtain test results and are directly proportional to concentration of the analyte.
Preparation of standard for linearity (percentage in 50, 75, 100, 125 and 150) Acceptance criteria
The relationship between the concentration of Ambroxol, Montelukast and Levocetrizine area of Ambroxol, Montelukast and Levocetrizine should be linear in the specified range and the correlation should not be less than 0.99.
Observation
The (Table 4 , Figures 1 and 2 ).
Accuracy
In accuracy we will inject 3 injections of 50% and 3 injections of 100% and 3 injections of 150%.
Sample preparation
Weigh the 10 tablets of Lezest-M and calculate average valve for 10 tablets then calculate it equivalent to 15 mg of ambroxol and 10 mg of Montelukast and 2.5 mg of Levocetrizine. Crush the tablets in motor and pestle. Weigh the fine powder which is equivalent to standard preparation and dissolved in 100 ml volumetric flask from the above stock solution pipette out 2.75 ml and transfer intp 10 ml volumetric flask and make up the volume with mobile phase (Table 5) . (Table 6 ).
Robustness and Ruggedness
Performing the validation by different analysts on different days (Tables 7 and 8 
